Chan Henry Lee Sells 920 Shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Stock

Key Points

• BeOne Medicines Ltd. SVP Chan Henry Lee sold 920 shares of the company's stock at an average price of $304.60, totaling $280,232.
• The company's stock experienced a 0.4% increase on the day of the sale, reaching $301.13, with a trading volume surpassing its average.
• Wall Street analysts have raised their price targets for BeOne Medicines, with recent estimates ranging from $330 to $350, while the stock currently has an overall "buy" rating.

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) SVP Chan Henry Lee sold 920 shares of the stock in a transaction dated Wednesday, July 30th. The stock was sold at an average price of $304.60, for a total value of $280,232.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Chan Henry Lee also recently made the following trade(s):

• On Monday, June 16th, Chan Henry Lee sold 422 shares of BeOne Medicines stock. The stock was sold at an average price of $266.50, for a total value of $112,463.00.
• On Friday, June 6th, Chan Henry Lee sold 700 shares of BeOne Medicines stock. The stock was sold at an average price of $256.11, for a total transaction of $179,277.00.

BeOne Medicines Stock Performance

NASDAQ:ONC traded up $3.26 during trading hours on Monday, reaching $302.27. The stock had a trading volume of 129,620 shares, compared to its average volume of 436,361. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.96 and a quick ratio of 1.71. BeOne Medicines Ltd. - Sponsored ADR has a 52 week low of $158.84 and a 52 week high of $308.87. The company's 50 day moving average price is $263.99. The company has a market capitalization of $33.13 billion, a PE ratio of -81.26 and a beta of 0.27.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.71) by $1.93. The business had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.12 billion. BeOne Medicines had a negative return on equity of 7.55% and a negative net margin of 9.40%. Equities research analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 EPS for the current year.

Institutional Investors Weigh In On BeOne Medicines

Institutional investors have recently modified their holdings of the stock. Envestnet Asset Management Inc. bought a new position in shares of BeOne Medicines during the second quarter valued at approximately $15,061,000. Oppenheimer Asset Management Inc. bought a new position in shares of BeOne Medicines during the second quarter valued at approximately $7,150,000. Asset Management One Co. Ltd. purchased a new position in shares of BeOne Medicines during the second quarter valued at $4,951,000. Slow Capital Inc. bought a new position in shares of BeOne Medicines during the second quarter valued at approximately $4,377,000. Finally, Public Employees Retirement System of Ohio bought a new position in shares of BeOne Medicines during the second quarter valued at approximately $3,491,000. 48.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Royal Bank Of Canada boosted their target price on shares of BeOne Medicines from $311.00 to $349.00 and gave the company an "outperform" rating in a research report on Wednesday, July 16th. Morgan Stanley lifted their price target on BeOne Medicines from $313.00 to $330.00 and gave the company an "overweight" rating in a research note on Friday, June 27th. JPMorgan Chase & Co. increased their price target on BeOne Medicines from $321.00 to $345.00 and gave the stock an "overweight" rating in a report on Thursday, July 17th. TD Securities restated a "buy" rating and issued a $334.00 target price on shares of BeOne Medicines in a research note on Thursday, April 24th. Finally, Guggenheim raised their price objective on shares of BeOne Medicines from $348.00 to $350.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $327.56.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.